NBTX
Nanobiotix S.A.
NASDAQ · Healthcare · Biotechnology · FR
$38.80
−3.00%Year over year
Reported trailing growth
- Revenue
- -41.8%
- EBITDA
- -77.2%
- EBIT
- -2.5%
- EPS
- +29.2%
- Free cash flow
- -6.1%
- Operating cash flow
- -4.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +83.8%
- EBITDA
- +82.2%
- EBIT
- +84.2%
- Net income
- +64.8%
- EPS
- +65.3%
- Free cash flow
- -66.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025